Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.

@article{Khodai2011SingleAC,
  title={Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.},
  author={Tansi Khodai and Debbie Chappell and Clare Christy and Paul Cockle and Jim E. Eyles and D Boyd Hammond and Katrina Gore and Michael J McCluskie and Dana M. Evans and Susanne Lang and Peter T. Loudon and Tim J. Townend and Paul Wright and Kate West and Helen Bright},
  journal={Clinical and vaccine immunology : CVI},
  year={2011},
  volume={18 10},
  pages={1702-9}
}
Despite several attempts to develop an effective prophylactic vaccine for HSV-2, all have failed to show efficacy in the clinic. The most recent of these failures was the GlaxoSmithKline (GSK) subunit vaccine based on the glycoprotein gD with the adjuvant monophosphoryl lipid A (MPL). In a phase 3 clinical trial, this vaccine failed to protect from HSV-2 disease, even though good neutralizing antibody responses were elicited. We aimed to develop a superior, novel HSV-2 vaccine containing either… CONTINUE READING
Highly Cited
This paper has 23 citations. REVIEW CITATIONS
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…